Alembic Pharma Q4 net up 12% to Rs 251 cr
Alembic Pharmaceuticals Limited (APL) has reported a 12 per cent growth in net profit for the March quarter, to Rs 251 crore, which was Rs 225 crore during the same period the previous year. The company‘s net sales were increased six per cent to Rs 1,280 crore, as against Rs 1,207 crore.
On a full-year basis, the company’s net profit increased 42 per cent to Rs 1,178 crore for FY21 as against Rs 829 crore in FY20, while net sales were rose 17 per cent to Rs 5,393 crore (Rs 4,606 crore).
Mentioning on the results, Alembic Pharmaceuticals Limited managing director Pranav Amin stated that the fiscal was an “outstanding year”, with the company recording its highest-ever sales and profit.
He also added that “This was led by strong growth in the API and international businesses. The operating teams worked tirelessly through the pandemic to ensure critical supplies were uninterrupted.
The company filed 13 abbreviated new drug applications (ANDAs) during the fourth quarter and a total of 29 during the full fiscal year 2020-21. Alembic’s R&D spend stood at 12 per cent of revenue at Rs 670 crore for the year.
Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company. It has it,s headquarters in Vadodara city of Gujarat India.